Aspirin trelamine hydrochloride is under clinical development by Techfields Pharma and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I drugs for Pulmonary Embolism have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Aspirin trelamine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aspirin trelamine hydrochloride overview

Aspirin trelamine hydrochloride (TF-0023) is under development for the treatment of type 2 diabetes, myocardial infarction, pulmonary embolism, chronic heart failure. It is administered by transdermal route as a spray and also by cutaneous route as powder for solution.. The drug candidate is developed based on transdermal/topical drug delivery platform. The platform allows drugs to penetrate membrane barriers faster.

It was also under development for recovery of ischemic stroke, pulmonary edema and acute respiratory distress syndrome (ARDS) and pneumonia caused by coronavirus disease 2019 (COVID-19).

For a complete picture of Aspirin trelamine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.